Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle-Reference-Cited by-同舟云学术

Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle

Published:2018-08-03 Issue:21 Volume:61 Page:9473-9499
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Mackman Richard L.¹^ORCID,Steadman Victoria A.²^ORCID,Dean David K.²,Jansa Petr¹,Poullennec Karine G.²,Appleby Todd¹,Austin Carol²,Blakemore Caroline A.²,Cai Ruby¹,Cannizzaro Carina¹,Chin Gregory¹,Chiva Jean-Yves C.²,Dunbar Neil A.²,Fliri Hans³,Highton Adrian J.²,Hui Hon¹,Ji Mingzhe¹,Jin Haolun¹,Karki Kapil¹,Keats Andrew J.²,Lazarides Linos²,Lee Yu-Jen¹,Liclican Albert¹,Mish Michael¹,Murray Bernard¹,Pettit Simon B.²,Pyun Peter¹,Sangi Michael¹,Santos Rex¹,Sanvoisin Jonathan²,Schmitz Uli¹,Schrier Adam¹,Siegel Dustin¹,Sperandio David¹,Stepan George¹,Tian Yang¹,Watt Gregory M.²,Yang Hai¹,Schultz Brian E.¹^ORCID

Affiliation:

1. Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States

2. Selcia Ltd., Fyfield Business and Research Park, Fyfield Road, Ongar, Essex CM5 0GS, United Kingdom

3. Cypralis Ltd., Babraham Research Campus, Cambridge CB22 3AT, United Kingdom

Funder

Gilead Sciences

Selcia Ltd.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link